Nasdaq Extends Bid Price Compliance Deadline to February 2027
KTTA sits 74% above its 52-week low of $0.281 on light trading volume (0.4× avg).
Summary
Nasdaq granted Pasithea Therapeutics a 180-day extension to February 16, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company may implement a reverse stock split to meet the requirement.
Key Events · Legal and Risk Events · KTTA
-
Nasdaq Extension Granted
Nasdaq granted a 180-day extension to February 16, 2027, for Pasithea Therapeutics to regain compliance with the $1.00 minimum bid price requirement.
-
Delisting Risk Remains
If the company fails to regain compliance by the new deadline, Nasdaq will issue a delisting notice, though the company could appeal to a hearings panel.
-
Reverse Split Considered
The company may implement a reverse stock split of its outstanding securities to raise the stock price above $1.00.
-
Prior Non-Compliance
The company was first notified of non-compliance on February 20, 2026, and had until August 19, 2026, to regain compliance.
Analysis · KTTA · Life Sciences
Pasithea Therapeutics received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, pushing the deadline to February 16, 2027. The company remains at risk of delisting if it cannot lift its stock price above $1.00, and it may pursue a reverse stock split to achieve compliance. This extension provides temporary relief but does not resolve the underlying issue.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 37.5% of the 3434 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KTTA was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.